Detalhe da pesquisa
1.
Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
PLoS Pathog
; 14(2): e1006934, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481552
2.
A nano-luciferase expressing human coronavirus OC43 for countermeasure development.
Virus Res
; 339: 199286, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016504
3.
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
Sci Transl Med
; 16(748): eadj4504, 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38776389
4.
A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity.
Nat Commun
; 14(1): 1371, 2023 03 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36914616
5.
Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potential.
bioRxiv
; 2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37425890
6.
Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
Cell Host Microbe
; 27(5): 710-724.e7, 2020 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32407709
7.
Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
mBio
; 10(5)2019 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31530669
8.
Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.
Cell Rep
; 25(5): 1214-1224, 2018 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380413